Based in Gaithersburg, Maryland, Novavax is a biotechnology company focused on the discovery, development, and commercialization of vaccines for serious infectious diseases. The company employs approximately 950 full-time staff and operates across the United States, Europe, and international markets.
The company's primary platform combines recombinant protein technology, nanoparticle formulation, and its proprietary Matrix-M adjuvant to enhance immune response. Novavax's commercial product is NVX-CoV2373, a COVID-19 vaccine marketed under the brand names Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted. The vaccine is approved for use as a primary series and booster doses in both homologous and heterologous regimens across adult and adolescent populations.
Beyond COVID-19, the company is advancing R21/Matrix-M, an adjuvanted malaria vaccine candidate in development. Revenue is primarily generated through COVID-19 vaccine sales, though the company's commercial trajectory has been impacted by changing market dynamics in the vaccine space. Novavax was incorporated in Delaware in 1987.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $2.58 | $2.72 | +309.8% | |
| 2024 | $-1.23 | $-1.23 | +77.3% | |
| 2023 | $-5.41 | $-5.41 | +35.7% | |
| 2022 | $-8.42 | $-8.42 | +64.1% | |
| 2021 | $-23.44 | $-23.44 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001000694-26-000007 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001000694-25-000004 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0001000694-24-000007 | SEC ↗ |
| 2022-12-31 | 2023-02-28 | 0001000694-23-000005 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001000694-22-000004 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001000694-21-000004 | SEC ↗ |
| 2019-12-31 | 2020-03-11 | 0001104659-20-031944 | SEC ↗ |
| 2018-12-31 | 2019-03-18 | 0001144204-19-014640 | SEC ↗ |
| 2017-12-31 | 2018-03-14 | 0001144204-18-014686 | SEC ↗ |
| 2016-12-31 | 2017-02-27 | 0001144204-17-011334 | SEC ↗ |
| 2015-12-31 | 2016-02-29 | 0001144204-16-084770 | SEC ↗ |
| 2014-12-31 | 2015-02-27 | 0001144204-15-012379 | SEC ↗ |
| 2013-12-31 | 2014-03-12 | 0001144204-14-014965 | SEC ↗ |
| 2012-12-31 | 2013-03-12 | 0001144204-13-014545 | SEC ↗ |
| 2011-12-31 | 2012-03-14 | 0001144204-12-014910 | SEC ↗ |